Final-Program-ATS-2023-AP.vp

MONDAY • MAY 22

139

110 Persistent Hypercapnia After Acute Exacerbation of Chronic Obstructive Pulmonary Disease: An Indicator for Long-term Non-invasive Ventilation/ Z.J. Gandhi, WIlkes-Barre, PA 111 Flow Profiles Uncover and Correct Suboptimal Metered Dose Inhaler Technique/ S. King, Olten, Switzerland 112 Inhalation Technique Maintenance in COPD Patients Using the Albuterol Digihaler/ T. Wang, Chapel Hill, NC 113 Factors Influencing Correctness of the Inhalation Technique/ I. Domagala, Poland, Poland 114 App-Based Symptom Assessment Is Triggered by Inhaler Use Changes Preceding COPD Exacerbations/ M.B. Drummond, Chapel Hill, NC 115 Inhalation Parameter and Inhaler Usage Thresholds Preceding COPD Exacerbations in Patients Using the Albuterol Digihaler/ G.T. Ferguson, Farmington Hills, MI 116 Variable Obstruction Is Associated With Chronic Obstructive Pulmonary Disease Development and Faster Lung Function Decline: Finding From ECOPD Cohort Study/ F. Wu, Guangzhou, China 117 Bronchodilator Responsiveness, Small Airway Disease, and Spirometric Pattern Variability/ S. Fortis, Iowa City, IA 118 Estimating Rate of Lung Function Change Using Clinical Spirometry Data/ A. Balasubramanian, Baltimore, MD 119 Prediction of Exacerbations in Chronic Obstructive Pulmonary Disease Using Race-specific Versus Race-neutral Reference Equations/ J.H. Brems, Baltimore, MD 120 Persistent Airway Mucus Plugs and Changes in Lung Function in COPD/ S. Mettler, Boston, MA 121 Airway Mucus Plugs and Chronic Obstructive Pulmonary Disease Exacerbations/ V. Kim, Philadelphia, PA 122 Mortality Risk Reduction With Budesonide/Glycopyrrolate/Formoterol Fumarate Versus Fluticasone Furoate/Umeclidinium/Vilanterol in COPD: A Matching-Adjusted Indirect Comparison of Ethos and Impact/ D. Stolz, Freiburg, Germany 123 Plasma Omega-3 Fatty Acid Levels Associated With Reduced COPD Morbidity/ T. Kemper, Waco, TX

CLINICAL • TRANSLATIONAL POSTER DISCUSSION SESSION

B22

NEW TREATMENTS AND NOVEL TARGETS FOR COPD AND ALPHA-1

9:00 a.m. - 11:00 a.m.

Marriott Marquis Washington Marquis Ballroom, Salons 1-2 (Level M2)

Poster Viewing

9:00-9:45 9:45-11:00

Discussion

Chairing: D.L. Demeo, MD, Boston, MA

J.M. Wells, MD, MSPH, Birmingham, AL S. Raju, MD, MPH, Baltimore, MD 101 Twice-daily, Nebulized Ensifentrine Produced Significant Improvement in Week 12 Lung Function: Sub-group Analysis in the Phase 3 Trial Enhance-2/ K. Rickard, Raleigh, NC 102 Ensifentrine Reduced Healthcare Resource Utilization in Subjects With COPD: Results From Enhance-2, a Phase 3 Trial of Ensifentrine, a Dual PDE3/4 Inhibitor/ I. Barjaktarevic, Los Angeles, CA 103 Longitudinal Analysis of Clinical Outcomes in PiMZ Alpha-1 Antitrypsin Smokers From the Spiromics Cohort/ I. Barjaktarevic, Los Angeles, CA 104 Budesonide/Glycopyrrolate/Formoterol Fumarate Effects on Exacerbations of Chronic Obstructive Pulmonary Disease Based on Airflow Limitation: A Post-hoc Analysis of the KRONOS Study/ F.J. Martinez, New York, NY 105 Community Health Worker-supported Self-management Action Plan for Chronic Obstructive Pulmonary Disease Exacerbations: A Feasibility Intervention Trial/ W. Checkley, Baltimore, MD 106 The Feasibility and Efficacy of Heated Humidified Air Via Nasal Cannula for COPD Patients Post Exacerbation: An Open-label, Non-randomized Pilot Study/ T. Ho, Hamilton, Canada 107 Analysis From Phase II Clinical Trial, Alvelestat, NE (Neutrophil Elastase) Inhibitor in AATD-LD: Correlation Between Biomarker Response (Desmosine and Aa-val 360 ) and Clinical Outcome (SGRQ)/ J. Parkin, London, United Kingdom 108 The Protease-Antiprotease Balance in Alpha-1 Antitrypsin Deficiency/ M. Herron, Dublin, Ireland 109 Isoflavone Intake Associated With Decreased Chronic Obstructive Pulmonary Disease Morbidity/ E. Quiroz, Baltimore, MD

ATS 2023 • Washington, DC